TALICIA
Sep 09, 2024
Helicobacter pylori Infections Treatment: Emerging Molecular Targets
Helicobacter pylori infection is among the most widespread chronic bacterial infections globally, affecting roughly half of the world’s population. H. pylori is classified as a Class I carcinogen by the WHO and is recognized as a qualifying pathogen under the US FDA’s GAIN Act. It is the most significant known risk...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
